CompletedPhase 3

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

United States274 participantsStarted 2019-04-25

Plain-language summary

The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult-onset axial spondyloarthritis meeting Assessment of SpondyloArthritis International Society (ASAS) classification criteria
✓. Inflammatory back pain for at least 3 months
✓. Age at symptom onset of less than 45 years
✓. NO sacroiliitis (in Anterior-Posterior pelvis or sacroiliac x-ray)

What they're measuring

Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16

Timeframe: Week 16

Trial details

NCT IDNCT03928704

SponsorUCB Biopharma SRL

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-06-29

Results submitted2024-10-18

View on ClinicalTrials.gov More Nonradiographic Axial Spondyloarthritis trials